Implant shows success in treating posterior uveitis

Durham, NC-Results of a 9-month randomized, dose-masked, multicenter clinical trial of a fluocinolone acetonide sustained drug delivery system to treat posterior uveitis resulted in significant gains for the eyes that received implants when compared with fellow eyes that did not receive implants, said Glenn J. Jaffe, MD.

Related Videos
New optics textbook aims to be a compendium resource for the topic
Higher rates of repeat corneal crosslinking need found in younger patients
Dispersive ophthalmic viscosurgical device found to be safe, effective in clinical trials
© 2023 MJH Life Sciences

All rights reserved.